What You Should Know:
– Monogram Health, a Nashville, TN-based kidney disease benefit management and care delivery company has closed a $160 million Series B funding round led by TPG Capital, the private equity platform of global alternative asset firm TPG. The funding round also includes existing investors Frist Cressey Ventures and Norwest Venture Partners, as well as Humana Inc. and other notable national and regional strategic investors.
– Monogram is focused exclusively on managing chronic kidney disease (CKD) and end-stage renal disease (ESRD) at home. The company partners with health plans to provide their members with an evidence-based renal care model of clinical managed services, including complex case and disease management, utilization management, and medication therapy management, to improve patient outcomes and quality of life while dramatically reducing costs for the health care system.
– More than 10 percent of the U.S. adult population suffers from chronic kidney disease today, though many cases go untreated until their final stages due to the shortcomings of existing care models. Leveraging the company’s technology, next-generation artificial intelligence, evidence-based criteria, and managed services platform, Monogram’s clinical team partners closely with a patient’s entire care network to help them understand their condition, slow disease progression, and manage their unique care needs.
– Monogram currently operates its renal disease clinical managed services to manage benefits across 20 states in the U.S. and has built a national network of nephrologists that includes hundreds of leading kidney care specialists. In April it opened an operations center in Arizona to support its growth in Western states.
